Market News AIOpen the app

Celldex Therapeutics, Inc. shares news about its Barzolvolimab trials for chronic hives.

ResultsRead the original at sec.gov
Neutral

The 8-K attaches a press release on Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 but includes no trial results in the filing, leaving Celldex's outlook unchanged.

CLDX · Celldex Therapeutics, Inc.

AI read · Neutral

The AI's read

The 8-K attaches a press release saying Celldex announced results from two Phase 3 EMBARQ-CSU trials of barzolvolimab. The filing text does not include the actual trial outcomes, so it provides no new basis to change Celldex's outlook.

Get alerts for CLDX

Follow Celldex Therapeutics, Inc. (CLDX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CLDX
Free on the App Store and Google Play, or on the web.